Antisense Polynucleotide Agents Targeting PNPLA3 for NAFLD Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Nonalcoholic Fatty Liver Disease (NAFLD) lack pharmacologic options, and existing therapies primarily focus on weight loss and managing secondary conditions, with no effective therapies available to directly address the underlying pathophysiology of the disease.
Innovation Solution
Development of antisense polynucleotide agents that target and inhibit the expression of the Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, which is associated with NAFLD, by binding to nucleic acids encoding PNPLA3 and interfering with its normal function, thereby reducing triglyceride accumulation in the liver.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If weight loss and management of secondary conditions are used as treatments for NAFLD, then the disease progression can be slowed, but no direct pharmacologic treatment addresses the underlying pathophysiology
Solution Approach 1:
The patent extracts and targets the specific pathological mechanism (PNPLA3 gene expression) from the complex disease process of NAFLD. By using antisense polynucleotide agents that specifically bind to PNPLA3 mRNA, the treatment isolates and addresses the root cause rather than managing multiple secondary conditions, thereby improving reliability while simplifying the treatment approach.
Solution Approach 2:
The antisense polynucleotide agents serve as intermediary molecules that mediate between the administered therapy and the target gene expression. These agents specifically bind to PNPLA3 mRNA and prevent its translation, creating a targeted pharmacologic intervention that directly addresses the underlying pathophysiology without requiring complex lifestyle modifications.
2Object-generated harmful factors
If antisense polynucleotide agents target PNPLA3 gene expression, then triglyceride accumulation is reduced, but the complexity of the therapeutic agent increases
Solution Approach 1:
The patent replaces complex lifestyle interventions (diet, exercise) with a molecular-level pharmacologic mechanism. The antisense polynucleotide agents use biochemical specificity (complementary base pairing with PNPLA3 mRNA) rather than mechanical or physical approaches, enabling precise targeting of triglyceride accumulation at the gene expression level despite the molecular complexity of the agents themselves.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antisense polynucleotide agents significantly inhibit PNPLA3 gene expression, leading to decreased triglyceride accumulation and reduced severity of NAFLD symptoms, providing a therapeutic approach for treating and preventing NAFLD-related conditions.
Implementation Method 1
The agents include a nucleotide sequence that is at least about 80% complementary over its entire length to the equivalent region of the nucleotide sequence of the PNPLA3 gene
Data Source
AI summary
The invention relates to polynucleotide agents targeting a Patatin-Like Phospholipase Domain Containing 3 (PNPLA3) gene, and methods of using such polynucleotide agents to inhibit expression of a PNPLA3 gene and methods of treating subjects having Nonalcoholic Fatty Liver Disease (NAFLD) and/or a PNPLA3-associated disorder.